Table 4.
Clinical trials of ICD‐based therapy synergized with immunotherapy
| ClinicalTrials.gov identifier | Therapeutic agents | Immunotherapeutic agents | Tumor | Recruitment status |
|---|---|---|---|---|
| NCT01637532 | Carbo/Caelyx or doxorubicin | Tocilizumab (anti‐IL‐6) and IFN‐α | Recurrent ovarian cancer | Completed; phase 2 |
| NCT02406183 | Radiation therapy | Ipilimumab (anti‐CTLA‐4) | Melanoma | Completed; phase 1 |
| NCT03380130 | Selective internal radiation therapy | Nivolumab (anti‐PD‐1) | Hepatocellular carcinoma | Completed; phase 2 |
| NCT05082259 | ASTX660 | Pembrolizumab (anti‐PD‐1) | Triple negative breast cancer | Not yet recruiting; phase 1 |
| NCT05034055 | Radiation | Atezolizumab (anti‐PD‐L1) and Tiragolumab (anti‐TIGIT) | Non‐small cell lung cancer | Not yet recruiting; phase 2 |
| NCT05019534 | Vemurafenib oral tablet | Camrelizumab (anti‐PD‐1) and Cetuximab (anti‐EGFR) | BRAF V600E‐mutated/MSS metastatic colorectal cancer | Recruiting; phase 1 |
| NCT04262687 | Capecitabine and Oxaliplatin | Pembrolizumab (anti‐PD‐1) and Bevacizumab (anti‐VEGF) |
Colorectal cancer metastatic High immune infiltrate Microsatellite stable |
Recruiting; phase 2 |
| NCT04558684 | Oxaliplatin, Capecitabine, and radiotherapy | Camrelizumab (anti‐PD‐1) | Rectal cancer | Active, not recruiting; phase1/2 |
| NCT03944252 | Cetuximab | Avelumab (anti‐PD‐L1) | Squamous cell anal carcinoma | Unknown; phase 2 |
| NCT05307198 | Oxaliplatin and Capecitabine | Sintilimab (anti‐PD‐1) | Rectal neoplasms | Not yet recruiting; phase 2 |
| NCT03388190 | 5‐Fluorouracil, oxaliplatin and leucovorin | Nivolumab (anti‐PD‐1) | Colorectal cancer metastatic | Active, not recruiting; phase 2 |
| NCT03801304 | Vinorelbine | Atezolizumab (anti‐PD‐L1) | Non‐small cell lung cancer | Active, not recruiting; phase 2 |
| NCT03206073 | Pexa‐Vec | Tremelimumab (anti‐CTLA‐4) and Durvalumab (anti‐PD‐L1) | Colorectal cancer | Active, not recruiting; phase 2 |
| NCT04043195 | Oxaliplatin | Nivolumab (anti‐PD‐1) and Ipilumumab (anti‐CTLA‐4) | Advanced non‐small cell lung cancer | Recruiting, phase1/2 |
| NCT04463368 | Melphalan | Nivolumab (anti‐PD‐1) and Ipilumumab (anti‐CTLA‐4) | Uveal melanoma | Recruiting; phase 1 |
| NCT02865811 | Pegylated liposomal doxorubicin | Pembrolizumab (anti‐PD‐1) | Ovarian cancer; fallopian tube cancer; peritoneal cancer | Active, not recruiting; phase 2 |
| NCT02580058 | Pegylated liposomal doxorubicin | Avelumab (anti‐PD‐L1) | Ovarian cancer | Active, not recruiting; phase 3 |